AI DEVELOPMENT

OpenAI to Begin Testing Ads in ChatGPT, Expands $8 Go Plan Globally

OpenAI has announced a significant shift in its business strategy, revealing plans to begin testing advertising inside ChatGPT while also expanding its paid ChatGPT Go subscription to more users worldwide.

According to the company, ads will start rolling out in the coming weeks for adult users in the United States who are using the free and ChatGPT Go tiers. OpenAI emphasized that these ads will be clearly labeled, visually separated from AI-generated responses, and will not influence how ChatGPT answers questions. The company says its core model behavior, safety standards, and response quality will remain unchanged.

This move marks OpenAI’s first direct experiment with in-product advertising for ChatGPT, signaling a new revenue stream beyond subscriptions and enterprise licensing. As usage of ChatGPT continues to grow globally, the company has been under increasing pressure to balance operating costs while keeping the service accessible to free users.

At the same time, OpenAI confirmed the global expansion of ChatGPT Go, its $8-per-month plan. Previously limited to select regions, the Go tier is now available in all markets where ChatGPT operates, including the U.S. The plan offers higher usage limits and additional features compared to the free version, positioning it as a more affordable middle ground between free access and higher-priced premium subscriptions.

OpenAI described the Go expansion as part of a broader effort to give users more flexibility in how they access ChatGPT, especially in regions where higher-priced plans may be less practical.

The announcement also reflects a broader trend across AI platforms, many of which are exploring hybrid monetization models that combine subscriptions with advertising. However, OpenAI appears cautious in its approach, repeatedly stressing transparency and user trust as central to the ad rollout.

For now, the ad test will remain limited in scope. OpenAI says it will closely monitor user feedback before deciding whether to expand ads to other regions or plans, signaling that this experiment could shape the future direction of ChatGPT’s business model.

Source: Open AI

Robi’s Insights:

• Ads in ChatGPT could help keep free access viable as usage scales, reducing pressure to gate features behind higher-priced plans.

• Clear labeling and separation suggest OpenAI is prioritizing trust to avoid disrupting core user workflows.

• The $8 Go plan creates a more accessible upgrade path for users who need higher limits without enterprise pricing.

• Hybrid monetization mirrors trends across digital platforms balancing growth and sustainability.

• For users, ads may become the trade-off for continued free AI assistance.

• OpenAI’s cautious rollout signals that user feedback will directly shape future monetization decisions.

OTHER IN AI DEVELOPMENTS

Cursor Shows AI Agents Can Build Million-Line Software Autonomously: In a new blog, Cursor revealed it ran hundreds of coordinated AI coding agents for weeks, with GPT-5.2 alone generating a fully functional 3M+ line web browser from scratch in under a week, outperforming Claude Opus 4.5 in long autonomous runs and signaling a major shift in the economics of software development.

Source: Cursor

SOCIAL MEDIA

Elon Musk and OpenAI Escalate Public Feud Ahead of April Trial

In response, OpenAI CEO Sam Altman accused Musk of “cherry-picking” material to fit a legal narrative. Altman published his own notes alleging Musk had proposed ambitious plans during OpenAI’s early days, including raising $80 billion to fund a self-sustaining city on Mars and outlining a long-term succession structure that would place control of artificial general intelligence under Musk’s children.

OpenAI further escalated the dispute by releasing a blog post titled “The truth Elon left out,” highlighting what it called missing context and inconsistencies between Musk’s legal filings and Brockman’s journal entries. The company argued that the documents, when viewed in full, tell a very different story about OpenAI’s evolution.

Musk, meanwhile, struck a defiant tone on social media, tweeting, “Can’t wait to start the trial. The discovery and testimony will blow your mind.” Reports indicate he is seeking up to $134 billion in damages, raising the stakes in one of the tech industry’s most consequential legal battles.

Source: Open AI

OTHER IN SOCIALS

Google Pledges Gemini Will Remain Ad-Free Amid ChatGPT Ad Tests: Google confirmed that Gemini will stay free of advertising, drawing a clear contrast with OpenAI as it prepares to begin testing ads in ChatGPT for free-tier users in the coming weeks.

Source: Business Insider

HEALTH

AI Accelerates Cancer Drug Discovery by Identifying Promising CDK9 Inhibitors

Scientists are increasingly using artificial intelligence to speed up cancer drug discovery, and a new study demonstrates how AI can uncover promising treatment candidates more efficiently than traditional approaches. The research highlights the use of AI-driven virtual screening to identify potential inhibitors of cyclin-dependent kinase 9 (CDK9), a protein strongly associated with cancer cell growth and survival.

The study was carried out by researchers from the Sbarro Institute, the National Cancer Institute – Pascale Foundation, and the University of Pisa. CDK9 was selected as a target due to its critical role in regulating gene transcription and cell proliferation, with abnormal activity observed in several aggressive cancer types.

The AI system predicted which molecules were most likely to bind effectively to CDK9, significantly narrowing down the number of candidates requiring experimental testing.

Through this computational process, researchers identified 14 potential CDK9 inhibitors. These compounds were then tested in cellular models of cervical and breast cancer. Two of the molecules demonstrated a notable ability to reduce cancer cell viability, indicating strong therapeutic potential at an early stage.

Although further validation, optimization, and clinical testing are required, the findings highlight the growing role of artificial intelligence in biomedical research. The study shows how AI can shorten discovery timelines, reduce costs, and help scientists identify novel cancer treatment candidates with greater precision than conventional drug discovery methods.

Source: News Medical

DAILY AI TOOL

AI Tool You Did Not Know You Needed

• Problem: You have a brilliant idea for a web or mobile app, but turning that concept into a functional application feels overwhelming. Setting up development environments, writing boilerplate code, and deploying the app can be time-consuming and technically challenging.

• AI Tool: Bolt.new is an AI-powered platform that enables you to build, edit, and deploy full-stack web and mobile applications directly from your browser, using simple prompts.

• Solution: Some tools can help you streamline the development process. They allow you to describe your app in plain English, automatically generate the necessary code, and handle deployment, all within your browser.

PROMPT OF THE DAY

Find Great Collaboration Opportunities in Your Niche

SPOT THE FAKE

Can you outsmart AI?

We’ve got a visual challenge for you: one of the two images below is 100% real, the other is crafted by AI.

Click option below A or B. 👇

BEFORE YOU GO

Ready to take your AI journey further?

• For the latest AI updates and insights Click Here 👉 Explore our Weekly Newsletter

• For in-depth AI tutorials and updates 👉 Subscribe to our YouTube Channel

AT THE END

Craving more AI chaos?

Read Daily AI News at BitBiased.AI. Support us by following us on LinkedIn and X ( Twitter ).

Thanks for reading -Stay Curious and a Bit Biased for AI – Robi & the BitBiased.AI team